Kazuo Kobayashi

Dr. Kazuo Kobayashi

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 August 2020 in In Vivo
Verified
Journal Article
Closed access
PDF file
Kazuo KobayashiKazuo Kobayashi
Kazuo Kobayashi
YIYusuke Iikura
Yusuke Iikura
MHMakoto Hiraide
Makoto Hiraide
TYTakashi Yokokawa
Takashi Yokokawa
TATakeshi Aoyama
Takeshi Aoyama
THToshihiro Hama
Toshihiro Hama
Background/Aim: Immune-related adverse events (irAEs) are associated with the efficacy of immune-checkpoint inhibitors in patients with melanoma and non-small cell lung cancer. We therefore evaluated the relationship between irAEs and nivolumab efficacy against metastatic renal cell carcinoma. Patients and Methods: The medical records of 53 consecutive patients were reviewed and analyzed. Results: Median overall survival was significantly better in patients who showed irAEs at any time compared to patients without irAEs (p=0.013). We identified irAEs in 24 of 53 patients (45.3%), including four patients (7.5%) with grade 3 events. Multivariate analysis also revealed that risk factors for the onset of irAEs were positively associated with a platelet-to-lymphocyte ratio <156 before nivolumab treatment (p=0.006). Conclusion: Development of irAEs was associated with survival outcomes of nivolumab treated patients with metastatic renal cell carcinoma.

14 January 2020 in Oncology
Verified
Journal Article
Closed access
PDF file
Kazuo KobayashiKazuo Kobayashi
Kazuo Kobayashi
KSKenichi Suzuki
Kenichi Suzuki
MHMakoto Hiraide
Makoto Hiraide
TATakeshi Aoyama
Takeshi Aoyama
TYTakashi Yokokawa
Takashi Yokokawa
THToshihiro Hama
Toshihiro Hama
Purpose: Immune-related adverse events (irAEs) have been associated with the efficacy of programmed cell death protein 1 (PD-1) inhibitors in patients with urothelial cancer. We therefore evaluated the relationship between irAEs and pembrolizumab efficacy in urothelial cancer patients. Methods: Patients with urothelial cancer who were treated with pembrolizumab in a second-line setting or later between January 2018 and December 2018 were identified by reviewing their medical records from the Cancer Institute Hospital, Japanese Foundation for Cancer Research. Data were updated as of December 31, 2018. Kaplan-Meier curves for overall survival (OS) and time to treatment failure (TTF) according to irAE grade were evaluated using the log-rank test. Risk factors for exacerbation of irAEs were also evaluated with multivariate analysis. Results: In this retrospective study, 43 patients received pembrolizumab. We identified irAEs in 22 of the 43 patients (51.2%), including 11 patients (25.6%) with grade 2 or 3 events. In patients with irAE grade 0 or 1, median TTF was 127 days, and median OS was 160 days according to the Kaplan-Meier method. On the other hand, in patients with irAE grade ≥2, median TTF and OS were not reached. Multivariate analysis also revealed that risk factors for exacerbation of irAEs (to grade ≥2) were positively associated with lymphocyte count at baseline (>2,000/µL) before pembrolizumab treatment (p = 0.021). Conclusions: Development of irAEs was associated with survival outcome of pembrolizumab treatment in patients with advanced urothelial cancer.

14 February 2019 in Oncology
Verified
Journal Article
Closed access
PDF file
Kazuo KobayashiKazuo Kobayashi
Kazuo Kobayashi
KKKazuyoshi Kawakami
Kazuyoshi Kawakami
TYTakashi Yokokawa
Takashi Yokokawa
TATakeshi Aoyama
Takeshi Aoyama
KSKenichi Suzuki
Kenichi Suzuki
THToshihiro Hama
Toshihiro Hama
Purpose: Hand-foot skin reaction (HFSR) can deteriorate quality of life in patients receiving regorafenib. Cutaneous toxicity is a main adverse effect of multikinase inhibitors and has also been associated with clinical outcome. This study assessed the association between the antitumor efficacy of regorafenib and HFSR in patients with metastatic colorectal cancer (mCRC). Methods: Patients who received regorafenib at 160 mg/day during the first 3 weeks of each 4-week cycle were divided into subgroups based on whether they developed HFSR between May 2013 and October 2015. Estimates of overall survival and progression-free survival were calculated using the Kaplan-Meier method. Results: Ninety-seven patients received at least one dose of regorafenib in this retrospective study. Of these patients, 81.4% (n = 79) experienced HFSR of any grade, and 34.0% (n = 33) had grade 3 HFSR. Among those patients with HFSR at any time during the study, 68.0% (n = 66) underwent the first HFSR event (any grade) during cycle 1. Both overall survival and progression-free survival were improved in patients who had HFSR grade ≥2 at any time compared with those who had HFSR grade ≤1. Multivariate logistic regression analysis revealed a history of HFSR grade ≥2 induced by capecitabine as a significant risk factor for severe HFSR (grade ≥2). Conclusions: Patients with mCRC treated using regorafenib who experienced severe HFSR showed better overall survival than patients without severe HFSR. Severe HFSR may offer an early surrogate marker for the efficacy of regorafenib in patients with mCRC.

2 November 2017 in Oncology Research
Verified
Journal Article
Open access
KKKazuyoshi Kawakami
Kazuyoshi Kawakami
TYTakashi Yokokawa
Takashi Yokokawa
Kazuo KobayashiKazuo Kobayashi
Kazuo Kobayashi
TSTakahito Sugisaki
Takahito Sugisaki
KSKenichi Suzuki
Kenichi Suzuki
THToshihiro Hama
Toshihiro Hama
Adherence has become an important issue in modern oncology treatment. Most studies have included heterogeneous target tumor types, regimens, and therapy settings. Our study focused on capecitabine during capecitabine plus oxaliplatin (XELOX) treatment as an adjuvant therapy for colorectal cancer. The main aims of this study were to evaluate real-life adherence to capecitabine and to investigate candidate factors that might decrease adherence. We studied 338 consecutive patients who received XELOX treatment between December 1, 2011, and April 30, 2015, at the Cancer Institute Hospital of the Japanese Foundation for Cancer Research. Our study assessed adherence to capecitabine through patient-reported treatment diaries and interviewed nonadherents to determine the reasons for not taking capecitabine at a pharmaceutical outpatient clinic. We calculated the adherence rate in a cycle as: number of times the patient took capecitabine/28. Relative dose intensities and factors associated with deteriorating adherence to capecitabine were retrospectively surveyed from electronic patient records. Uni- and multivariate logistic regression analyses were used to investigate factors associated with optimal adherence. The study covered 282 patients who received 2,055 cycles of XELOX. Median adherence rate was 94.0% in the first cycle, and median relative dose intensity of capecitabine was 77.8%. The most common reasons for nonadherence were nausea/vomiting and diarrhea. The presence of the following factors was not significantly associated with adherence: ECOG performance status ≥1 (p = 0.715), clinical stage (p = 0.408), primary tumor site (p = 0.576), age ≥70 years at study entry (p = 0.757), female gender (p = 0.504), and not living alone (p = 0.579). The adherence rate from this study was significantly higher than the adherence from metastatic settings. Adherence-enhancing interventions for capecitabine in XELOX treatment as adjuvant therapy comprised management of nausea/vomiting and diarrhea.

26 February 2021 in Cancer Chemotherapy and Pharmacology
Verified
Journal Article
Closed access
PDF file
Kazuo KobayashiKazuo Kobayashi
Kazuo Kobayashi
ESErika Sugiyama
Erika Sugiyama
ESEiji Shinozaki
Eiji Shinozaki
TWTakeru Wakatsuki
Takeru Wakatsuki
MTMasataka Tajima
Masataka Tajima
KYKensei Yamaguchi
Kensei Yamaguchi

1 October 2019 in Patient Preference and Adherence
Verified
Journal Article
Open access
PDF file
KKKazuyoshi Kawakami
Kazuyoshi Kawakami
TWTakeru Wakatsuki
Takeru Wakatsuki
ASAzusa Soejima
Azusa Soejima
Kazuo KobayashiKazuo Kobayashi
Kazuo Kobayashi
TYTakashi Yokokawa
Takashi Yokokawa
THToshihiro Hama
Toshihiro Hama
Introduction: Regorafenib is an oral multikinase inhibitor for the treatment of metastatic colorectal cancer (mCRC). The clinical factors that may affect adherence to regorafenib remain unclear. The aim of this study was to evaluate adherence to regorafenib with mCRC and to identify factors that might affect adherence to regorafenib. Methods: A total of 108 consecutively enrolled Japanese patients with mCRC received regorafenib. Adherence was measured by pharmacists using pill counts and a self-reported treatment diary for patients at a pharmaceutical outpatient clinic. The median relative dose intensities of regorafenib and the factors adversely affecting adherence were retrospectively surveyed. Logistic regression analysis was then performed using patient socio-demographic factors and clinical factors. Results: A total of 96 patients were included in the analysis. The median adherence rate was 61.7% in the first cycle. The median relative dose intensity was 57.1%. The most common reason for non-adherence was a hand-foot-skin reaction (35.6%). On multivariate analysis, increased non-adherence to regorafenib was significantly associated with sex (female) [odds ratio (OR) = 4.36; 95% confidence interval (CI): 1.43–13.22, p = 0.01]. Discussion: Hand-foot-skin reactions and female sex were associated with lower adherence to regorafenib. Since these factors could be associated with lower adherence to regorafenib, it would be useful to consider these factors when assessing adherence.